Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Desensitization to timothy grass pollen targets the immune system, specifically aiming to reduce or eliminate allergic responses in individuals sensitized to this common environmental allergen. The process is achieved through allergen immunotherapy, which can be administered via subcutaneous injections (allergy shots) or sublingual tablets/extracts. The goal is to retrain the immune system so that it becomes tolerant of timothy grass pollen, thereby reducing symptoms of allergic rhinitis and asthma during pollen season.
Gradual reprogramming from allergic inflammation toward immune tolerance by introducing gradually increasing amounts of timothy grass pollen allergens, leading to reduced IgE production and increased regulatory T cell activity.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immune System (desensitization to timothy grass pollen).